Advertisements


Denali Therapeutics: Key Catalysts Coming Up For This Neurodegenerative Disease Pioneer

Denali Therapeutics: Key Catalysts Coming Up For This Neurodegenerative Disease Pioneer.....»»

Category: topSource: seekingalphaJun 12th, 2019

Why Shares of Denali Therapeutics Are Skyrocketing

Shares of Denali Therapeutics Inc (NASDAQ: DNLI) are racing toward their 52-week high following a clinical pipeline update concerning the company's Parkinson's disease pipeline. read more.....»»

Category: blogSource: benzingaAug 6th, 2020

Biogen, Denali Therapeutics collaborate on LRRK2 program for Parkinson"s Disease

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 6th, 2020

Jefferies starts Denali Therapeutics at Buy ahead of "lots of catalysts in 2020"

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 24th, 2020

Denali Therapeutics announces ODD, Rare Pediatric Disease Designation for DNL310

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 11th, 2019

Denali Therapeutics reports Q2 EPS (56c), consensus (60c)

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 7th, 2020

Kazia Therapeutics receives Rare Pediatric Disease Designation for paxalisb

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 7th, 2020

54 Stocks Moving in Friday"s Pre-Market Session

Gainers Kazia Therapeutics Limited (NASDAQ: KZIA) shares rose 128.5% to $9.71 in pre-market trading after the FDA granted rare pediatric disease designation to paxalisib for Diffuse Intrinsic Pontine Glioma. read more.....»»

Category: blogSource: benzingaAug 7th, 2020

Denali Therapeutics decides to advance DNL151 into late stage clinical studies

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 6th, 2020

Denali Therapeutics stock rockets into record territory after Biogen investment and collaboration

Shares of Denali Therapeutics Inc. rocketed 29% into record territory in premarket trading Thursday, after Biogen Inc.....»»

Category: topSource: marketwatchAug 6th, 2020

Bill Gates: We will have a coronavirus vaccine, but the disease will keep coming back if there"s a US "leadership vacuum"

Mike Cohen/Getty Images for The New York Times; Samantha L.....»»

Category: topSource: businessinsiderJul 30th, 2020

Denali Therapeutics announces Sanofi commences dosing DNL758 in Phase 1b study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 29th, 2020

Durham biotech uses new funding to acquire gene therapy for eye disease

A Hatteras backed early stage life science company has used its new funding to acquire the exclusive rights to a gene therapy platform targeting eye disease. On Wednesday, Durham-based Atsena Therapeutics announced that it has acquired the exclusi.....»»

Category: topSource: bizjournalsJul 29th, 2020

Protara Therapeutics receives Rare Pediatric Disease designation for TARA-002

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 28th, 2020

Inhibikase Therapeutics files for IPO with plans to raise funds for trials of Parkinson"s disease treatment

Inhibikase Therapeutics Inc., a clinical-stage pharmaceutical company developing trea.....»»

Category: topSource: marketwatchJul 23rd, 2020

State links stopping virus now to safely reopening schools later

"With the urgency around school reopenings, just around the corner, if we do not get the community disease transmission rates down, we're really threatening the most important reopenings we have coming around Labor Day," Rubin said......»»

Category: topSource: bizjournalsJul 16th, 2020

Regenxbio provides update on rare neurodegenerative disease programs

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 8th, 2020

2 boys" deaths halt S.F. company"s rare disease gene therapy trial

Two boys died in a critical gene therapy trial against a genetic disease, forcing the company behind the therapy and regulators to halt the study. Audentes Therapeutics Inc., a San Francisco company that was sold in January to Astellas Pharma o.....»»

Category: topSource: bizjournalsJun 29th, 2020

Seelos Therapeutics begins preclinical study of SLS-007 in Parkinson"s Disease

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 25th, 2020

Ovid Therapeutics receives Rare Pediatric Disease Designation for OV101

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 19th, 2020

As one hopeful Alzheimer"s, ALS drug fizzles, Peninsula biotech brings up a second

Denali Therapeutics Inc. and partner Sanofi paused clinical studies of an experimental drug aimed at two crippling neurological diseases but said they would accelerate work on a second drug that they hope to put into clinical trials early next year. D.....»»

Category: topSource: bizjournalsJun 10th, 2020